Oxford Genetics announces adeno-associated virus collaboration with MeiraGTx

From Drug Discovery Today - December 5, 2017

The collaboration will enable Oxford Genetics and MeiraGTx to develop novel adeno-associated virus (AAV) vectors, as well as packaging and producer cell lines. The companies aim to create a fully scalable AAV production system that can satisfy the requirements for increased viral vector yields, process robustness and product efficacy.

Dr Ryan Cawood, CEO at Oxford Genetics, said: We are delighted to be working alongside the MeiraGTx team on such an exciting project, which will take us another step forward in our vision to deliver breakthrough technologies to the biotherapeutic industry.

By creating advanced AAV production systems we aim to power the expansion of gene therapy as it moves towards addressing the more common disease indications that present technologies cannot satisfy.

Continue reading at Drug Discovery Today »